Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment

Bradley Schwartz, DO

Disclosures

December 03, 2020

The benefits of adding bone-protective agents, such as denosumab or bisphosphonates, to treatment in mHSPC are not yet certain. While some studies have shown no advantages, a nonstatistical trend toward improved bone PFS was shown in one trial.

Subgroup analyses from the CHAARTED trial suggest that chemohormonal therapy may be most beneficial for men with mHSPC with a high-volume disease burden.

Radiation therapy to the primary tumor is associated with prolonged survival and a tolerable toxicity profile, and should therefore be considered in men with de novo low-volume mHSPC. However, radiation therapy to the primary tumor does not appear to confer a survival benefit for men with de novo high-volume metastatic disease.

Radical prostatectomy in men with mHSPC in combination with optimal systemic therapy is one of a number of novel methods currently being evaluated in a clinical trial, but it should not be considered outside of a clinical trial. Numerous studies are enrolling patients with mHSPC worldwide and should be considered for all interested patients.

Access the Cancer of the Prostate: ESMO Clinical Practice Guidelines, The National Institute for Health and Care Excellence Guidance – Prostate Cancer: Diagnosis and Management, the Prostate Cancer Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN), and the NCCN Guidelines Updates: Management of Prostate Cancer for recommendations for prostate cancer screening, diagnosis, and therapeutic strategies.

Learn more about treatment selection for patients with metastatic prostate cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....